TipRanks
Alnylam Pharmaceuticals (MX:ALNY)
:ALNY
Mexico Market
ALNY
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (ALNY) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ALNY Analyst Ratings

Strong Buy
22Ratings
Strong Buy
19 Buy
3 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$6,468.76
▲(16.55% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $6,468.76 with a high forecast of $9,429.43 and a low forecast of $4,388.97. The average price target represents a 16.55% change from the last price of $5,550.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4387":"$4,387","9430":"$9,430","5647.75":"$5,647.8","6908.5":"$6,908.5","8169.25":"$8,169.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9429.4335465,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6468.762857145301,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4388.97270528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.39K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4387,5647.75,6908.5,8169.25,9430],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5550,5848.4179651153845,6146.835930230769,6445.2538953461535,6743.671860461538,7042.0898255769225,7340.507790692308,7638.925755807692,7937.343720923077,8235.761686038462,8534.179651153845,8832.597616269231,9131.015581384616,{"y":9429.4335465,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5550,5620.674065934254,5691.348131868508,5762.022197802762,5832.696263737015,5903.370329671269,5974.044395605523,6044.718461539777,6115.392527474031,6186.066593408285,6256.7406593425385,6327.4147252767925,6398.088791211047,{"y":6468.762857145301,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5550,5460.690208098462,5371.380416196923,5282.070624295385,5192.760832393846,5103.451040492308,5014.1412485907695,4924.83145668923,4835.521664787692,4746.211872886153,4656.902080984615,4567.592289083077,4478.282497181538,{"y":4388.97270528,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8560,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8380,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8380,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8380,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6975,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6975,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6975,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5649.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5649.69,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5420,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5150.16,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5549,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5550,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$9,429Average Price Target$6,469Lowest Price Target$4,389
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:ALNY
Jeffrey Walch
Bernstein
Bernstein
$6,446.3
Buy
16.15%
Upside
Reiterated
09/16/26
Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)
Morgan Stanley Analyst forecast on MX:ALNY
Michael Ulz
Morgan Stanley
Morgan Stanley
$5,143.33
Hold
-7.33%
Downside
Reiterated
09/11/26
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
Jefferies Analyst forecast on MX:ALNY
Faisal Khurshid
Jefferies
Jefferies
$3,943.22→$4,457.55
Hold
-19.68%
Downside
Reiterated
09/08/26
Alnylam price target raised to $260 from $230 at JefferiesAlnylam price target raised to $260 from $230 at Jefferies
H.C. Wainwright Analyst forecast on MX:ALNY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$7,800.71
Buy
40.55%
Upside
Reiterated
09/02/26
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
Barclays Analyst forecast on MX:ALNY
Eliana Merle
Barclays
Barclays
$7,714.99
Buy
39.01%
Upside
Reiterated
09/01/26
Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on MX:ALNY
Cory Kasimov
Evercore ISI
Evercore ISI
$5,575.37
Buy
0.46%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on MX:ALNY
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$5,451.93
Buy
-1.77%
Downside
Reiterated
08/31/26
Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Truist Financial Analyst forecast on MX:ALNY
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Lakefront Biotherapeutics (NASDAQ: LKFT) and BioNTech SE (NASDAQ: BNTX)
Citi Analyst forecast on MX:ALNY
Eric Joseph
Citi
Citi
$5,829.1
Buy
5.03%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)
Bank of America Securities Analyst forecast on MX:ALNY
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$5,931.97
Buy
6.88%
Upside
Reiterated
08/31/26
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
Piper Sandler Analyst forecast on MX:ALNY
Edward Tenthoff
Piper Sandler
Piper Sandler
$8,383.62
Buy
51.06%
Upside
Reiterated
08/31/26
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
BMO Capital Analyst forecast on MX:ALNY
David Lebowitz
BMO Capital
BMO Capital
$5,451.93
Buy
-1.77%
Downside
Reiterated
08/30/26
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
Canaccord Genuity Analyst forecast on MX:ALNY
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$7,354.96
Buy
32.52%
Upside
Reiterated
08/28/26
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
Wells Fargo Analyst forecast on MX:ALNY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$5,417.64→$4,388.97
Hold
-20.92%
Downside
Assigned
08/14/26
Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo
J.P. Morgan Analyst forecast on MX:ALNY
Jessica Fye
J.P. Morgan
J.P. Morgan
$6,429.16
Buy
15.84%
Upside
Reiterated
08/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on MX:ALNY
Jeffrey Walch
Bernstein
Bernstein
$6,446.3
Buy
16.15%
Upside
Reiterated
09/16/26
Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)
Morgan Stanley Analyst forecast on MX:ALNY
Michael Ulz
Morgan Stanley
Morgan Stanley
$5,143.33
Hold
-7.33%
Downside
Reiterated
09/11/26
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
Jefferies Analyst forecast on MX:ALNY
Faisal Khurshid
Jefferies
Jefferies
$3,943.22→$4,457.55
Hold
-19.68%
Downside
Reiterated
09/08/26
Alnylam price target raised to $260 from $230 at JefferiesAlnylam price target raised to $260 from $230 at Jefferies
H.C. Wainwright Analyst forecast on MX:ALNY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$7,800.71
Buy
40.55%
Upside
Reiterated
09/02/26
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
Barclays Analyst forecast on MX:ALNY
Eliana Merle
Barclays
Barclays
$7,714.99
Buy
39.01%
Upside
Reiterated
09/01/26
Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on MX:ALNY
Cory Kasimov
Evercore ISI
Evercore ISI
$5,575.37
Buy
0.46%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Stifel Nicolaus Analyst forecast on MX:ALNY
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$5,451.93
Buy
-1.77%
Downside
Reiterated
08/31/26
Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Truist Financial Analyst forecast on MX:ALNY
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (NASDAQ: ALNY), Lakefront Biotherapeutics (NASDAQ: LKFT) and BioNTech SE (NASDAQ: BNTX)
Citi Analyst forecast on MX:ALNY
Eric Joseph
Citi
Citi
$5,829.1
Buy
5.03%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)
Bank of America Securities Analyst forecast on MX:ALNY
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$5,931.97
Buy
6.88%
Upside
Reiterated
08/31/26
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
Piper Sandler Analyst forecast on MX:ALNY
Edward Tenthoff
Piper Sandler
Piper Sandler
$8,383.62
Buy
51.06%
Upside
Reiterated
08/31/26
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
BMO Capital Analyst forecast on MX:ALNY
David Lebowitz
BMO Capital
BMO Capital
$5,451.93
Buy
-1.77%
Downside
Reiterated
08/30/26
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
Canaccord Genuity Analyst forecast on MX:ALNY
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$7,354.96
Buy
32.52%
Upside
Reiterated
08/28/26
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
Wells Fargo Analyst forecast on MX:ALNY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$5,417.64→$4,388.97
Hold
-20.92%
Downside
Assigned
08/14/26
Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo
J.P. Morgan Analyst forecast on MX:ALNY
Jessica Fye
J.P. Morgan
J.P. Morgan
$6,429.16
Buy
15.84%
Upside
Reiterated
08/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), OnKure Therapeutics (NASDAQ: OKUR) and Alnylam Pharma (NASDAQ: ALNY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
AXGNAxoGen
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months
Keay NakaeChardan Capital
Success Rate
24/39 ratings generated profit
62%
Average Return
+5.47%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +5.47% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
20/28 ratings generated profit
71%
Average Return
+25.49%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +25.49% per trade.
2 Years
David LebowitzBMO Capital
Success Rate
31/43 ratings generated profit
72%
Average Return
+40.83%
Copying David Lebowitz's trades and holding each position for 2 Years would result in 72.09% of your transactions generating a profit, with an average return of +40.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
19
24
34
35
28
Buy
17
14
19
23
19
Hold
7
6
10
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
44
63
67
55
In the current month, ALNY has received 47 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 6,468.76.
Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is $30.21 with a range of $17.70 to $50.56. The previous quarter’s EPS was $20.60. ALNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALNY is $30.21 with a range of $17.70 to $50.56. The previous quarter’s EPS was $20.60. ALNY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $24.33B with a range of $21.43B to $25.39B. The previous quarter’s sales results were $21.97B. ALNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.
Next quarter’s sales forecast for ALNY is $24.33B with a range of $21.43B to $25.39B. The previous quarter’s sales results were $21.97B. ALNY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ALNY has Performed in-line its overall industry.

ALNY Stock Forecast FAQ

What is MX:ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 6,468.76.
    What is MX:ALNY’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 16.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 19 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s share price target?
            The average share price target for Alnylam Pharmaceuticals is 6,468.76. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $9,429.43 ,and the lowest forecast is $4,388.97. The average share price target represents 16.55% Increase from the current price of $5,550.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Alnylam Pharmaceuticals?
                To buy shares of MX:ALNY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.